Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

The concept of SGLT2-inhibition, once regarded as a non-physiological approach to glycemia control, now finds a foundational relevance in risk-modification for cardiovascular, kidney, and metabolic outcomes, spanning beyond type-2 diabetes. Major studies have proven meaningful improvements in various clinical outcomes, with different SGLT2-i agents. Apart from glycosuria, SGLT2-inhibition is associated with several patho-physiological effects, which may contribute to the clinical benefits seen with these agents. This narrative review is an attempt to appraise the different patho-physiological effects mediated by SGLT2-inhibition, based on contemporary evidence. The review classifies these effects in the acronym of EUPHORIA, and grades the possible relevance of each effect, in improving clinical outcomes. © Journal of the Association of Physicians of India 2011.


Mangesh Tiwaskar, Sanjay Kalra, Ganapathi Bantwal, Arpandev Bhattacharya, Manisha Sahay, Uday Jadhav, Ameya Joshi, A K Das, Dinesh Khullar, Manash Baruah, Hitesh Punyani, Kamal Kishor, Kimi Shetty, Jignesh Ved. SGLT2-inhibition and Vascular Euphoria a Reconciliation of Vascular Health and Disease Homeostasis. The Journal of the Association of Physicians of India. 2021 Apr;69(4):11-12

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 34470191

View Full Text